Literature DB >> 19011297

Testosterone in chronic heart failure.

C Malkin1, T Jones, K Channer.   

Abstract

Chronic heart failure is common and can be described as a syndrome characterized by impairment of cardiac function associated with a maladaptive metabolic and neurohormonal axis. The thesis that testosterone replacement therapy may be helpful as a treatment for chronic heart failure may seem at first to be unlikely. Testosterone therapy is widely believed to be deleterious to the cardiovascular system and there is a common misconception that the excess of ischaemic heart disease in young and middle-aged males compared to females is a direct effect of endogenous serum testosterone levels. In this chapter we will present the published evidence of the effects of endogenous and therapeutic testosterone on the heart and the human cardiovascular system with an emphasis on the pathologic syndrome of chronic heart failure. There is developing evidence that of all morbid populations, patients with chronic heart failure in particular are likely to benefit from testosterone treatment since the natural history is that of progressive disordered metabolism with catabolic excess and androgen imbalance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19011297     DOI: 10.1159/000176053

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  12 in total

1.  Adult-onset idiopathic hypogonadotropic hypogonadism: possible aetiology, clinical manifestations and management.

Authors:  Jiang-Feng Mao; Min Nie; Shuang-Yu Lu; Xue-Yan Wu
Journal:  Asian J Androl       Date:  2010-06-07       Impact factor: 3.285

Review 2.  Testosterone and heart failure.

Authors:  Maurizio Volterrani; Giuseppe Rosano; Ferdinando Iellamo
Journal:  Endocrine       Date:  2012-06-24       Impact factor: 3.633

3.  Combined inhibition of aromatase activity and dihydrotestosterone supplementation attenuates renal injury in male streptozotocin (STZ)-induced diabetic rats.

Authors:  Michaele B Manigrasso; R Taylor Sawyer; Zachary M Hutchens; Elizabeth R Flynn; Christine Maric-Bilkan
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-01

Review 4.  Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials.

Authors:  Weiwei Wang; Ting Jiang; Chunyu Li; Jun Chen; Kejiang Cao; Lian-Wen Qi; Ping Li; Wei Zhu; Baoli Zhu; Yan Chen
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

5.  Signaling responses after exposure to 5 alpha-dihydrotestosterone or 17 beta-estradiol in norepinephrine-induced hypertrophy of neonatal rat ventricular myocytes.

Authors:  Yevgeniya E Koshman; Mariann R Piano; Brenda Russell; Dorie W Schwertz
Journal:  J Appl Physiol (1985)       Date:  2009-12-31

Review 6.  Androgen receptor (AR) in cardiovascular diseases.

Authors:  Chiung-Kuei Huang; Soo Ok Lee; Eugene Chang; Haiyan Pang; Chawnshang Chang
Journal:  J Endocrinol       Date:  2016-01-14       Impact factor: 4.286

Review 7.  Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment.

Authors:  Ilpo Huhtaniemi
Journal:  Asian J Androl       Date:  2014 Mar-Apr       Impact factor: 3.285

8.  Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure.

Authors:  Ahmad Mirdamadi; Mohammad Garakyaraghi; Ali Pourmoghaddas; Alireza Bahmani; Hamideh Mahmoudi; Mojgan Gharipour
Journal:  Biomed Res Int       Date:  2014-07-06       Impact factor: 3.411

Review 9.  Welcoming low testosterone as a cardiovascular risk factor.

Authors:  M Maggio; S Basaria
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

10.  Characterization of the vasodilatory action of testosterone in the human pulmonary circulation.

Authors:  Alyson M Smith; Robert T Bennett; T Hugh Jones; Mike E Cowen; Kevin S Channer; Richard D Jones
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.